ICON Public (NASDAQ:ICLR) Given “Outperform” Rating at William Blair

William Blair reiterated their outperform rating on shares of ICON Public (NASDAQ:ICLR) in a research report released on Tuesday,Benzinga reports.

A number of other research analysts have also recently weighed in on the stock. Evercore ISI cut their price objective on shares of ICON Public from $360.00 to $350.00 and set an “outperform” rating on the stock in a research report on Tuesday, October 8th. Leerink Partners reiterated an “outperform” rating and set a $255.00 price target (down from $270.00) on shares of ICON Public in a report on Tuesday, November 19th. Leerink Partnrs raised shares of ICON Public to a “strong-buy” rating in a research note on Wednesday, September 18th. Barclays cut their target price on ICON Public from $330.00 to $275.00 and set an “overweight” rating on the stock in a research note on Friday, October 25th. Finally, Redburn Atlantic began coverage on ICON Public in a report on Monday, October 14th. They issued a “neutral” rating and a $311.00 price target on the stock. Four investment analysts have rated the stock with a hold rating, eleven have issued a buy rating and one has given a strong buy rating to the company’s stock. Based on data from MarketBeat.com, the company presently has an average rating of “Moderate Buy” and a consensus target price of $287.00.

ICON Public Stock Performance

ICON Public stock opened at $200.24 on Tuesday. The company has a quick ratio of 1.34, a current ratio of 1.34 and a debt-to-equity ratio of 0.35. ICON Public has a twelve month low of $183.38 and a twelve month high of $347.72. The company’s 50-day moving average price is $211.31 and its 200-day moving average price is $270.81. The company has a market cap of $16.52 billion, a PE ratio of 22.32, a price-to-earnings-growth ratio of 1.54 and a beta of 1.20.

ICON Public (NASDAQ:ICLR) last issued its quarterly earnings data on Wednesday, October 23rd. The medical research company reported $3.35 earnings per share for the quarter, missing the consensus estimate of $3.72 by ($0.37). The company had revenue of $2.03 billion for the quarter, compared to the consensus estimate of $2.13 billion. ICON Public had a return on equity of 11.91% and a net margin of 9.00%. The company’s revenue was down 1.2% compared to the same quarter last year. During the same period in the previous year, the firm earned $3.10 earnings per share. On average, equities research analysts forecast that ICON Public will post 13.42 EPS for the current fiscal year.

Institutional Inflows and Outflows

Several hedge funds and other institutional investors have recently added to or reduced their stakes in ICLR. Foyston Gordon & Payne Inc bought a new stake in shares of ICON Public in the 3rd quarter valued at about $11,672,000. Icon Wealth Advisors LLC lifted its holdings in ICON Public by 861.1% during the third quarter. Icon Wealth Advisors LLC now owns 13,215 shares of the medical research company’s stock worth $3,797,000 after buying an additional 11,840 shares during the period. Whittier Trust Co. boosted its position in ICON Public by 12.3% during the 3rd quarter. Whittier Trust Co. now owns 4,020 shares of the medical research company’s stock valued at $1,155,000 after acquiring an additional 441 shares in the last quarter. Sara Bay Financial purchased a new position in shares of ICON Public in the 3rd quarter valued at $1,143,000. Finally, Steph & Co. raised its position in shares of ICON Public by 3.7% in the 4th quarter. Steph & Co. now owns 1,560 shares of the medical research company’s stock worth $327,000 after acquiring an additional 55 shares in the last quarter. 95.61% of the stock is currently owned by institutional investors.

ICON Public Company Profile

ICON Public Limited Company, a clinical research organization, provides outsourced development and commercialization services in Ireland, rest of Europe, the United States, and internationally. The company specializes in the strategic development, management, and analysis of programs that support various stages of the clinical development process from compound selection to Phase I-IV clinical studies.